Sensorion SA, a clinical-stage biopharmaceutical company, develops therapies for the treatment of inner ear disorders in France. More Details
+ 1 more risk
Adequate balance sheet and overvalued.
Share Price & News
How has Sensorion's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALSEN is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ALSEN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.
7 Day Return
1 Year Return
Return vs Industry: ALSEN exceeded the French Biotechs industry which returned 35.2% over the past year.
Return vs Market: ALSEN exceeded the French Market which returned 48.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Sensorion's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDid The Underlying Business Drive Sensorion's (EPA:ALSEN) Lovely 310% Share Price Gain?
8 months ago | Simply Wall StHow Much Did Sensorion's(EPA:ALSEN) Shareholders Earn From Share Price Movements Over The Last Five Years?
1 year ago | Simply Wall StIs Sensorion (EPA:ALSEN) Weighed On By Its Debt Load?
Is Sensorion undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALSEN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALSEN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALSEN is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: ALSEN is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALSEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALSEN is good value based on its PB Ratio (3.7x) compared to the FR Biotechs industry average (4.3x).
How is Sensorion forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALSEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALSEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALSEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALSEN's revenue (15.6% per year) is forecast to grow faster than the French market (6.8% per year).
High Growth Revenue: ALSEN's revenue (15.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALSEN's Return on Equity is forecast to be high in 3 years time
How has Sensorion performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALSEN is currently unprofitable.
Growing Profit Margin: ALSEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALSEN is unprofitable, and losses have increased over the past 5 years at a rate of 12.8% per year.
Accelerating Growth: Unable to compare ALSEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALSEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).
Return on Equity
High ROE: ALSEN has a negative Return on Equity (-15.38%), as it is currently unprofitable.
How is Sensorion's financial position?
Financial Position Analysis
Short Term Liabilities: ALSEN's short term assets (€66.4M) exceed its short term liabilities (€4.3M).
Long Term Liabilities: ALSEN's short term assets (€66.4M) exceed its long term liabilities (€5.2M).
Debt to Equity History and Analysis
Debt Level: ALSEN is debt free.
Reducing Debt: ALSEN has no debt compared to 5 years ago when its debt to equity ratio was 19.6%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ALSEN has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALSEN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Sensorion current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALSEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALSEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALSEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALSEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALSEN's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nawal Ouzren (41 yo)
Ms. Nawal Ouzren has been Chief Executive Officer of Sensorion SA (Sensorion SAS) since April 2017. Ms. Ouzren had been an Independent Director at Inventiva S.A. since May 7, 2019 until April 2021. She has...
Experienced Management: ALSEN's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: ALSEN's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.2%.
Sensorion SA's company bio, employee growth, exchange listings and data sources
- Name: Sensorion SA
- Ticker: ALSEN
- Exchange: ENXTPA
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €153.439m
- Shares outstanding: 76.72m
- Website: https://www.sensorion.com
Number of Employees
- Sensorion SA
- 375, rue du Professeur Joseph Blayac
Sensorion SA, a clinical-stage biopharmaceutical company, develops therapies for the treatment of inner ear disorders in France. It engages in developing USHER-GT, a gene therapy development program to res...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 19:16|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.